Here in Tokyo with several members of the regulatory team, we had fruitful discussions about our journey in supporting numerous companies in the rare disease space. We touched also on the recently introduced incentives by MHLW to expedite the development and registration of orphan drugs in Japan. Very proud of our achievements in supporting PMDA consultation, development, approval and commercialization of numerous orphan drugs in Japan.
